Cardiology

Will angiotensin receptor II blockers play a role in epilepsy prevention?
Study examines whether ARB therapy is associated with a decreased incidence of new onset epilepsy in patients with hypertension.
Early norepinephrine not associated with 24-hour mortality among blunt trauma, hemorrhagic shock patients
Study adds to the debate about use of vasopressors for these patients.

Common cardiovascular drugs and Paxlovid can cause drug-drug interactions: review

People who are taking common cardiovascular drugs and given Paxlovid (nirmatrelvir/ritonavir) are at risk of drug-drug interactions, according to a review in the Journal of the American College of Cardiology.
Health Canada approves two therapies for COVID-19 treatment

Single-dose Evusheld is now indicated for treating mild/moderate COVID-19 and Actemra IV is now approved for treating COVID-19 in hospitalized adults.
Type 2 Diabetes medication update

Selecting medications to manage hyperglycemia . . . and comorbidities,
DOAC dosing in older patients with nonvalvular atrial fibrillation

An oral anticoagulant is recommended for most patients aged ≥ 65 years with nonvalvular atrial fibrillation (NVAF), to reduce the risk of stroke.
Aspirin may benefit people with elevated lipoprotein-a (Lp(a))

Recognized as an independent risk factor for cardiovascular disease, there are no approved therapies.
Alberta pharmacists develop DOAC drug interactions management resource

Practice a tool compares drug interactions with the four marketed DOACs, focusing on interactions commonly encountered in thrombosis/cardiology-based practices
New Canadian guideline for using GLP-1 agonists and SGLT2 inhibitors for cardiorenal risk reduction

GLP-1 receptor agonists and SGLT2 inhibitors have proven cardiorenal benefits in patients with and without type 2 diabetes.
QUIZ: Vascular anomalies in childhood

Do you know when and how to treat hemangiomas, and when to refer?

Will angiotensin receptor II blockers play a role in epilepsy prevention?

Early norepinephrine not associated with 24-hour mortality among blunt trauma, hemorrhagic shock patients

Common cardiovascular drugs and Paxlovid can cause drug-drug interactions: review

Health Canada approves two therapies for COVID-19 treatment

Type 2 Diabetes medication update

DOAC dosing in older patients with nonvalvular atrial fibrillation

Aspirin may benefit people with elevated lipoprotein-a (Lp(a))

Alberta pharmacists develop DOAC drug interactions management resource

New Canadian guideline for using GLP-1 agonists and SGLT2 inhibitors for cardiorenal risk reduction

QUIZ: Vascular anomalies in childhood